Novartis Typhoid Vaccine Seeks Partner After Securing Clinical Trial Site
Executive Summary
Phase II study is ongoing in Pakistan, a year after Novartis convinced the Pakistani government to lift its ban on clinical trials. Antimalarials with a different mechanism of action than Coartem are in Phase I and II trials.
You may also be interested in...
Novartis Typhoid Vaccine Deal With India’s BioE Shows New Licensing Model
Biological E Limited will develop Novartis’ Vi-CRM197 beyond Phase II; the firm will gain rights to a second vaccine against typhoid and paratyphoid upon completion of proof of concept studies.
R&D For Diseases Of Developing Countries Could Be Driven By Pooled Funds
WHO committee backs use of pooled funds to finance R&D, nixes priority review vouchers and finds no need for data exclusivity. Novartis’ Paul Herrling, a committee member, notes that governments would be responsible for R&D costs.
R&D For Diseases Of Developing Countries Could Be Driven By Pooled Funds
WHO committee backs use of pooled funds to finance R&D, nixes priority review vouchers and finds no need for data exclusivity. Novartis’ Paul Herrling, a committee member, notes that governments would be responsible for R&D costs.